Telmisartan Pilot Study on Treatment Resistant Schizophrenia
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study is a 4-week pilot study for subjects with Schizophrenia or Schizoaffective
Disorder who have not experienced a significant relief of symptoms from current
anti-psychotic medication. The Investigators hypothesize that 4 weeks of telmisartan at 80mg
daily will alter glutamate and GABA in the brain as measured with 1H-Magnetic Resonance
Spectroscopy (MRS) after 4 weeks treatment.